THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Laurent Peyrin-Biroulet  ¹     Jessica Allegretti  ²     Brian G. Feagan  ³     Brian Bressler  ⁴     Gary Lichtenstein  ⁵     Gary KH Huang  ⁶     Matthew Germinaro  ⁶     Nicole Shipitofsky  ⁶     Lingjing Jiang  ⁶     Hongyan Zhang  ⁶     Tadakazu Hisamatsu  ⁷     Julian Panés  ⁸     Axel Dignass  ⁹     Bruce E. Sands  ¹⁰     David T. Rubin  ^11    
1 Nancy University Hospital, Université de Lorraine, Nancy, France
² Brigham and Women´s Hospital, Boston, United States
³ Alimentiv Inc, London, Canada
⁴ University of British Columbia, Vancouver, Canada
⁵ University of Pennsylvania School of Medicine, Philadelphia, United States
⁶ Janssen Research & Development, LLC, Spring House, United States
⁷ Kyorin University, Tokyo, Japan
⁸ Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
⁹ Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany
¹⁰ Icahn School of Medicine at Mount Sinai, New York, United States
¹¹ University of Chicago Medicine, Chicago, United States

Topic
Endoscopy, Histopathology, IBD

Session
IL-23-Blockers in IBD: Part 2

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)